Epitopea secures $14, in seed financing round led by Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital (CIC) and Fonds de solidarité FTQ
Epitopea, a transatlantic cancer immunotherapeutics company and global specialist in exploiting a new class of untapped tumour-specific antigens (TSAs), has secured a $13.6 million (£10.3 million) seed investment from a transatlantic syndicate of top-tier life sciences investors, including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital (CIC) and Fonds